PRKG1 and Parkinson disease: Moreover, in different toxin-induced or genetic PD models, treatment with terazosin—a PGK agonist—enhanced brain ATP and dopamine levels with the restoration of motor function, suggesting that stimulation of PGK and glycolytic activities could represent a possible therapeutic approach in the treatment of PD [174].